Alpha fetoprotein is a single chain a globulin, of molecular weight 68 000, normally unique to the fetus but often found in increased concentrations in plasma of children and non-pregnant adults with liver disease and some forms of malignant tumours. Alpha fetoprotein is produced in the developing fetus in equal amounts by the yolk sac and the fetal liver, but at about 12 weeks after conception the yolk sac degenerates and the fetal liver becomes the main site of synthesis. Fetal plasma a fetoprotein concentration reaches a peak value of 3 000 000 U/ml at a gestation of about 14 weeks. ' Alpha fetoprotein synthesis almost ceases at parturition and the infant plasma concentration falls exponentially from a mean of 50 000 U/ml to a typical adult concentration of less than 10 U/ml at 6 to 8 months of age.2
The observation that a fetoprotein synthesis does not cease entirely at term'-5 may be explained by the presence of fetal hepatocytes, which, though decreasing in number, sustain transient production of a fetoprotein during the early postnatal period. Any clinical condition that interferes with this physiological decline in fetal protein biosynthesis will disturb the usual fall in plasma a fetoprotein concentration. Such a mechanism has been postulated in neonatal viral hepatitis,6 where compensatory proliferation of hepatocytes produces rapid regeneration of liver tissue and restoration of hepatic a fetoprotein synthesis.
Since the onco-fetoprotein a fetoprotein was first identified electrophoretically in the cord blood of human infants, its merit as a general marker of perinatal disease has been studied intensively. Interassay imprecision expressed as percentage coefficient of variation was 3-9% at a mean a fetoprotein concentration of 50 U/ml and 3.5% at a mean concentration of 25 U/ml. Statistical methods. Data reduction was achieved with the aid of a desk top minicomputer, using established normal theory methods on age grouped a fetoprotein results, which yielded the following statistics together with their standard errors and 95% confidence limits'7: mean, median, standard deviation, and percentage coefficient of variation.
Previous studies on paediatric and adult a fetoprotein reference ranges prompted a simple logarithmic transformation of uncorrected a fetoprotein results and a fetoprotein results corrected for gestational age with re-application of the data reduction procedure. Linear (Y=mX+c) and exponential (ln(Y)=mX+ ln(c)) least squares regression analyses were performed on ungrouped a fetoprotein data paired with both uncorrected and corrected patient ages.
Results
An essential prerequisite to the lengthy derivation of age related plasma a fetoprotein reference ranges was the verification of underlying relations between plasma a fetoprotein concentration and patient age. Linear and exponential least squares regression analyses were performed on the entire set of 97 plasma a fetoprotein values matched in the first instance with patient age at sampling and then with patient age corrected for gestational age deficit at birth (Table 1) .
Results of linear regression analysis quickly confirmed earlier assumptions of a significant negative correlation (r=-0.42, n=97, p<001) between plasma a fetoprotein concentrations and uncorrected age. As expected the introduction of correction for gestational age produced a beneficial effect on the degree of correlation (r=-0-58, n=94, p<001) measured by linear regression. A remarkable doubling of the correlation coefficient, yielding an identical r value of -0-85 for both uncorrected data and data corrected for gestational age deficit, followed the application of exponential least squares regression. The latter findings were not attributable entirely to chance but could reasonably have been deduced from previous observations of the exponen Corrected age (weeks) for preterm infants=Chronological age (weeks) at time of blood sampling minus gestational age deficit (weeks).
Gestational age deficit =Number of weeks preterm at birth (term=40 weeks5-for example, infant X with an estimated gestational age at birth of 28 weeks was 6 weeks old at the time blood was collected for a fetoprotein determination. Gestational age deficit=40-28-that is, 12 weeks. Corrected age (weeks)=6-12-that is, -6 weeks. Table 3 . This latest statistical elabora- (Table 4) and of infant age adjusted for gestational age deficit ( (mainly post-excision) from two preterm babies (with gestational ages of 31 and 32 weeks) with benign sacrococcygeal teratoma were plotted on Tsuchida's graph'4 ( Fig. 3(a) ). Several values were located either at or above the upper limit of the '95% prediction band' without discernible clinical cause. When the patient ages were adjusted for gestational age deficit and the same plasma AFP data replotted on our revised reference range graph (Fig. 3(b) (Figure 3(b) ).
Assessment of the diagnostic potential of our a fetoprotein ranges in relation to non-malignant paediatric liver disease was impossible without resorting to previously published a fetoprotein data, there being no established cases in the group studied. Maximal serum a fetoprotein results collected by Zeltzer et al from 19 term infants with an established diagnosis of biliary atresia or hepatitis6
were plotted on the graph (Figure 3(b) ). Results of this retrospective comparison plot tended to suggest that earlier biochemical differentiation between neonatal hepatitis and biliary atresia may be realised by plasma a fetoprotein monitoring, although not without further study. Clearly, these preliminary findings must be treated with caution in view of the substantial methodological differences between Zeltzer's radial immunodiffusion technique and modern a fetoprotein radioimmunoassays and perhaps more importantly the assumed patient ages at sampling. Uncorrected patient age (weeks) Corrected patient age (weeks) Fig. 3(a) Serial plasma afetoprotein results from two preterm infants (@-4and ----0) in our study with benign sacrococcygeal teratoma plotted on the reference range graph of Tsuchida et al. 4 (b) Serial plasma a fetoprotein results from two preterm and three term infants (represented by black dots) in our study with benign sacrococcygeal teratoma plotted on the Glasgow (Yorkhill) reference range graph together with serum a fetoprotein data from two published cases of malignant tumour in infancy (pre-resection hepatoblastoma (A) and post-resection orchioblastoma (-) 3) and maximal serum afetoprotein results published for 19 term infants with biliary atresia (*) or hepatitis (Q).6
In conclusion, we have shown, despite the limited data available, the relative simplicity of deriving paediatric reference ranges for plasma a fetoprotein with the aid of gestational deficit adjustment and a single step data transformation. Our findings may encourage others to derive similar laboratory reference ranges for plasma a fetoprotein based on paediatric results obtained by local assay methods and thereby confirm or refute the value of plasma a fetoprotein as a marker for non-malignant disease in early infancy. 
